AltraVax acquires vaccine development technology package from Maxygen AltraVax, Inc sildenafil citrate 100mg ., a fresh, privately-held biopharmaceutical company, has obtained a vaccine advancement technology bundle from Maxygen, Inc. that provides AltraVax a special license to build up vaccines for infectious diseases and is definitely targeting influenza, cure for hepatitis B and HIV. The technology can compress vaccine development timelines, resulting in new vaccine possibilities that have the potential to boost and protect human wellness globally. Related StoriesBasic analysis for developing toxoplasma vaccine underwayResearch provides network marketing leads for new ways of develop HIV vaccineKey component of MRSA vaccine puzzle unearthedArthur Ventures Growth Fund, LLC is the lead investor in AltraVax.

Other Articles From "health":

Random Articles